Involving Esterase Patents (Class 435/19)
-
Publication number: 20130034873Abstract: The present invention relates to a method for the analysis of fat-soluble components, in particular dyes, from biological materials, in particular lipid rich foodstuffs, having an enrichment of the components and subsequent analysis. The method comprises a combination of extraction and separation steps and a subsequent analysis step. The invention further relates to an analytical kit and analytical equipment for carrying out the method. The method according to the invention is composed of a plurality of steps. The critical steps which are essential and characterize the invention are: 1. Pre-treatment of the sample to remove lipids. 2. Extracting the dyes into an extraction mixture by a specific solvent or solvent mixture. 3. Destruction of the oxidative sensible ingredients such as carotenoids prior to the final detection and quantification by eye or by optical enhancement.Type: ApplicationFiled: September 21, 2010Publication date: February 7, 2013Inventor: Florian J. Schweigert
-
Publication number: 20130034864Abstract: Methods for determining the occurrence or level of a mammalian protein in a sample and methods for determining the capability of a compound to transform or to inhibit the transformation of a selected mammalian protein in pro-phospholipase B form to an enzyme active phospholipase B form employ a pro-phospholipase B (PLB-II) mammalian protein which comprises at least one SU2 subunit comprising SEQ ID NO: 3 and having a molecular weight within the range of 30-60 kDa. Methods for determining the capability of a compound to enhance or inhibit the enzymatic activity of a selected protein having phospholipase B enzyme activity employ a protein comprising an activated form of such a pro-phospholipase B (PLB-II) mammalian protein.Type: ApplicationFiled: October 15, 2012Publication date: February 7, 2013Applicant: P&M VENGE ABInventor: P&M VENGE AB
-
Patent number: 8361774Abstract: A protein is described that has an amino acid sequence characterized by at least 90% sequence identity with SEQ ID NO: 24, the protein being capable of recognizing a sequence consisting of 5?-GCCGAG-3? within the double-stranded DNA and cleaving the substrate predominantly at 21/19 nucleotides from the recognition site. A method is also described that utilizes the protein for creating a DNA tag for use as a unique identifier for paired end sequencing of DNA or serial analysis of gene expression.Type: GrantFiled: December 21, 2007Date of Patent: January 29, 2013Assignee: New England Biolabs, Inc.Inventor: Richard D. Morgan
-
Publication number: 20130017557Abstract: The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: —measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) sPLA2 type HA mass and b) oxidized phospholipids on apolipoprotein B-IOO particles (OxPL/apoB), —combining said measurements, the combined value of sPLA2 type HA mass and OxPL/apoB being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.Type: ApplicationFiled: December 8, 2009Publication date: January 17, 2013Inventors: Ziad Mallat, Alain Tedgui, Sotirios Tsimikas, Joseph Witztum
-
Publication number: 20130017198Abstract: A novel mechanism by which after-depolarization occurs in cardiac myocytes has been discovered, involving calcium influx through the arachidonate-regulated calcium channel (ARCC) and the store-operated calcium channel (SOCC). Because after-depolarization of the myocyte is a major cause of cardiac arrhythmia, this discovery provides new approaches for treating and preventing heart disease. By down-regulating the activity of the ARCC or the SOCC, after-depolarization can be decreased and cardiac arrhythmia can be prevented, reduced, or eliminated. This can be accomplished using pharmaceuticals containing inhibitors of the ARCC or the SOCC, or by genetically modifying cells to reduce ARCC or SOCC activity. In addition, assays are disclosed using the ARCC or SOCC to discover potential anti-arrhythmic agents. Cellular and animal models of arrhythmia are disclosed in which the activity of the ARCC or SOCC is increased to promote after-depolarization and induce arrhythmia.Type: ApplicationFiled: March 25, 2011Publication date: January 17, 2013Applicant: THE UAB RESEARCH FOUNDATIONInventors: Paul Wolkowicz, Jian Huang
-
Publication number: 20120328596Abstract: The invention provides a use of platelet activating factor acetylhydrolase (PAF-AH) activity as a biomarker for severe or fatal anaphylaxis in a subject. The level of PAF-AH activity inversely correlates with the susceptibility to severe or fatal anaphylaxis. The use comprises assaying PAF-AH activity in a sample from the subject and comparing the measured activity to a reference value, wherein a lower level of measured PAF-AH activity relative to said reference level of PAF-AH activity indicates a presence of or susceptibility to severe or fatal anaphylaxis in the subject. A method for treating or preventing severe or fatal anaphylaxis in a subject is also provided. The method comprises increasing serum platelet activating factor acetylhydrolase (PAF-AH) concentration in the subject by administering to the subject, PAF-AH and/or a PAF receptor antagonist. A composition for treating severe or fatal anaphylaxis is also provided.Type: ApplicationFiled: September 3, 2012Publication date: December 27, 2012Applicant: ALLERTECH LABORATORY INC.Inventor: Peter VADAS
-
Publication number: 20120309037Abstract: The present invention provides methods and devices for detecting and identifying toxins, including but not limited to organophosphorus nerve agents and/or organophosphorus pesticides, in a sample. One embodiment of the present invention comprises a method for identifying an organophosphorus nerve agent and/or an organophosphorus pesticide, comprising: exposing a group of enzymes comprising human carboxylesterase 1, at least one mutant of human carboxylesterase 1, and acetylcholinesterase to a sample, wherein the enzymes are separate from each other and each enzyme binds at least one organophosphorus nerve agent or at least one organophosphorus pesticide; contacting the exposed enzymes with a fluid comprising an oxime and a substrate; and detecting a signal produced upon reaction of the substrate and the exposed enzymes, whereby detection of the signal identifies the organophosphorus nerve agent and/or the organophosphorus pesticide.Type: ApplicationFiled: December 8, 2010Publication date: December 6, 2012Inventors: Matthew Robert Redinbo, Andrew Clinton Hemmert, Jonathan Seaver Edwards
-
Publication number: 20120309036Abstract: The invention relates to an arrangement, comprising a solid carrier and a matrix arranged on the solid carrier, said matrix comprising at least one enzymatically convertible or modifiable molecule and comprising at least one enzyme that can be released by the conversion or modification of the molecule, said enzyme being capable of converting at least one color-changing substrate located in the matrix and/or on the solid carrier.Type: ApplicationFiled: February 9, 2011Publication date: December 6, 2012Inventors: Georg Gübitz, Eva Sigl, Andrea Hasmann, Marc Schröder, Konstantin Schneider, Alexandra Rollett, Franz Kaufmann, Andreas Hafner
-
DETECTION OF LYSOPHOSPHATIDYLCHOLINE FOR PROGNOSIS OR DIAGNOSIS OF A SYSTEMIC INFLAMMATORY CONDITION
Publication number: 20120301910Abstract: The present invention provides methods and compositions useful for the diagnosis or prognosis of a systemic inflammatory condition such as sepsis.Type: ApplicationFiled: April 18, 2012Publication date: November 29, 2012Applicant: BECTON, DICKINSON AND COMPANYInventors: Song Shi, Thomas Gentle, Richard Moore -
Patent number: 8318449Abstract: It is intended to provide an assay method whereby the activity of a lipid-modifying enzyme can be conveniently measured over a wide range and a drug capable of controlling a lipid-modifying enzyme with the use of this assay method. The above problem can be solved by, for example, a method of measuring the activity of a lipid-modifying enzyme which comprises the steps of (I) preparing a lipid micelle containing a biotinylated lipid and a substrate for the lipid-modifying enzyme; (II) bringing the lipid micelle prepared in the above step (I) into contact with the lipid-modifying enzyme; and (III) evaluating the activity of the lipid-modifying enzyme by applying an evaluation method using the proximity effect to the product obtained in the above step (II).Type: GrantFiled: November 16, 2009Date of Patent: November 27, 2012Assignee: Ajinomoto Co., Inc.Inventor: Naoyuki Fukuchi
-
Publication number: 20120288873Abstract: The disclosure includes assays and methods for screening for risk of Down syndrome and/or trisomy 21 in a fetus. The assays and methods comprise determining the level of at least one biomarker selected from mucin 13 (MUC13), bile salt-activated lipase (CEL), dipeptidyl peptidase 4 (DPP4), carboxypeptidase A1 (CPA1), amyloid precursor protein (APP) and tenascin-C (TNC-C) polypeptides in a test biological sample from a pregnant subject, wherein a decreased level of MUC13, CEL, DPP4, and/or CPA1 polypeptide and/or an increased level of APP and/or TNC-C polypeptide in the test biological sample compared to a corresponding reference biomarker polypeptide level indicates an increased risk of Down syndrome or trisomy 21 in the fetus. The disclosure also includes assays, compositions, immunoassays, and kits for performing the methods disclosed herein.Type: ApplicationFiled: May 9, 2012Publication date: November 15, 2012Applicant: UNIVERSITY HEALTH NETWORKInventors: Eleftherios P. Diamandis, Chan-Kyung Jane Cho, Eduardo Martinez Morillo
-
Publication number: 20120282238Abstract: The present invention relates to an in vitro method of diagnosis of a Plasmodium infection in a subject, by measuring the serum concentration of at least one secreted phospholipase A2 selected from the group consisting of GIIF, GV and GX sPLA2s, in said subject, from a blood sample. It also relates to a kit for carrying out said method and pharmaceutical compositions comprising a recombinant mammal GIIF, GV or GX sPLA2 or a combination thereof.Type: ApplicationFiled: December 3, 2010Publication date: November 8, 2012Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, MUSEUM NATIONAL D'HISTOIRE NATURELLE, UNIVERSITE DE NICE SOPHIA ANTIPOLISInventors: Christiane Deregnaucourt, Gérard Lambeau, Carole Guillaume, Joseph Schrevel
-
Patent number: 8304223Abstract: The invention relates to novel mutants of ?PLE, to vehicles containing the same and to their use in the production of enantiomer-enriched alcohols, carboxylic acids and esters.Type: GrantFiled: March 11, 2008Date of Patent: November 6, 2012Assignee: Enzymicals AGInventors: Uwe Bornscheuer, Anke Hummel, Dominique Böttcher, Elke Brüsehaber, Kai Doderer, Harald Trauthwein
-
Publication number: 20120276552Abstract: Methods for diagnosing prostate cancer and lung cancer are disclosed. The methods include obtaining a biological sample from a subject, determining a level of serum secretory phospholipase A2-IIA in the biological sample, comparing the level of serum secretory phospholipase A2-IIA with a baseline level of serum secretory phospholipase A2-IIA, and diagnosing prostate cancer or lung cancer in the subject. An elevated level of serum secretory phospholipase A2-IIA as compared to the baseline level correlates to a positive diagnosis of prostate cancer or lung cancer in the subject.Type: ApplicationFiled: January 5, 2011Publication date: November 1, 2012Applicant: UNIVERSITY OF CINCINNATIInventor: Shan Lu
-
Publication number: 20120276569Abstract: This invention relates to methods for determining the activity of Lp-PLA2 in at least one sample from an animal. The invention also relates to methods for determining the inhibition of Lp-PLA2 activity in samples from animals that are administered an Lp-PLA2 inhibitor.Type: ApplicationFiled: July 2, 2012Publication date: November 1, 2012Inventors: Yaping Shou, Yin-Fai SIU, George T. WALKER
-
Publication number: 20120269910Abstract: A method of testing a substance potentially active in the field of lipolysis comprising: preparing a substrate containing at least one triacylglycerol; placing this substrate in contact with a substance potentially active in the field of lipolysis, and with a lipoprotein lipase, in the presence of a cofactor of lipoprotein lipase, for a period of time sufficient to release at least in part one fatty acid of the triacylglycerol; and determining the capacity of inhibition of the release of the fatty acid resulting from the activity of the lipoprotein lipase, under the action of said potentially active substance, and evaluating the result of the inhibition which is either compared to the result obtained in the absence of the potentially active substance tested or compared with the result obtained in the presence of a known inhibitor acting as reference. Cosmetic and pharmaceutical uses are described.Type: ApplicationFiled: June 28, 2012Publication date: October 25, 2012Applicant: BASF Beauty Care Solutions France S.A.S.Inventors: Eric Perrier, Delphine Rival, Valérie Lamy
-
Patent number: 8293537Abstract: At least one embodiment of a stabilizing system includes a stabilizing agent present in an amount or concentration sufficient to completely or substantially prevent or reduce degradation or inactivation of a glycosylated hemoglobin (HbA1c) in a body fluid and a detection agent capable of detecting the HbA1c.Type: GrantFiled: October 18, 2010Date of Patent: October 23, 2012Inventors: Richard H. Selinfreund, Rakesh Vig, Richard P. Gill
-
Publication number: 20120264153Abstract: A method of detecting a phytase activity or a protease activity is described. The method comprises the steps of: (a) providing a composition comprising a phytate/protein complex in a liquid or a gel; wherein the phytate/protein complex provides a detectable property to the composition; (b) providing a sample that comprises or is suspected of comprising phytase activity and/or protease activity, wherein the phytase and/or protease activity is capable of causing a change in the detectable property of the composition; (c) contacting the composition with the sample; and (d) determining if there is a detectable change in detectable property of the composition.Type: ApplicationFiled: December 17, 2010Publication date: October 18, 2012Applicant: Danisco A/SInventor: Shukun Yu
-
Patent number: 8288117Abstract: It is an object of the present invention to provide: a dry analytical element for analyzing pancreatic lipase wherein the triglyceride is not transcribed on the support to contaminate a transportation slip or other analytical elements and wherein an additive solution of the triglyceride neither reaggregates nor precipitate, so that the dry analytical element is stable and is compatible with production. The present invention provides a dry analytical element for measuring pancreatic lipase contained in body fluid, which comprises triglyceride of long chain alkyl fatty acid having 12 to 22 carbon atoms, monoglyceride lipase, and a glycerin measurement reagent, and which comprises a water-impermeable support and at least one spreading or reagent layer, wherein a hydrophilic polymer at a weight ratio of 1.8:1 or greater with respect to the triglyceride is contained.Type: GrantFiled: March 24, 2009Date of Patent: October 16, 2012Assignee: Fujifilm CorporationInventors: Kentaro Nakamura, Shigeki Kageyama
-
Patent number: 8278063Abstract: The invention relates to bacteria, bacterial extracts, supernatants obtained from the culturing of said bacteria, polypeptides and compositions for degrading benzimidazole carbamate fungicides, carbanilate fungicides, sulfonamide herbicides, thioamide herbicides and/or synthetic pyrethroid insecticides. In particular, the invention relates to the identification of Nocardioides sp. which degrades benzimidazole carbamate fungicides, carbanilate fungicides, sulfonamide herbicides, thioamide herbicides and/or synthetic pyrethroid insecticides.Type: GrantFiled: June 27, 2008Date of Patent: October 2, 2012Assignee: Commonwealth Scientific and Industrial Research OrganisationInventors: Gunjan Pandey, Chris M. Coppin, Susan J. Dorrian, Robyn Russell, John Oakeshott
-
Patent number: 8278085Abstract: The invention provides human protein complexes with endonuclease activity, including tRNA splicing endonuclease activity and 3? end pre-mRNA endonuclease activity, and pre-ribosomal RNA cleavage activity. The invention also provides a splice variant of human Sen2, and human protein complexes comprising the variant. The invention provides human protein complexes with pre-ribosomal RNA cleavage activity. The invention also provides antibodies that immunospecifically bind to a complex described herein or a component thereof, and uses of such antibodies. The present invention also provides methods of preparing and purifying the complexes and uses of the complexes inter alia, in screening, diagnosis, and therapy.Type: GrantFiled: December 30, 2008Date of Patent: October 2, 2012Assignee: PTC Therapeutics, Inc.Inventors: Christopher R. Trotta, Sergey Paushkin
-
Publication number: 20120230943Abstract: The present invention relates to agents, and methods for identifying compounds, which agents and compounds are effective in the treatment, and more particularly, that inhibit cachexia, and its associated or related disorders and conditions. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by cachexia, and its associated or related disorders and conditions and/or cachexia, and its associated or related disorders and conditions, such as for example, cancer cachexia and cachexia associated with AIDS, autoimmune disorders, drug addiction, alcoholism, chronic inflammatory disorders, cirrhosis of the liver, anorexia and neurodegenerative disease. In particular, the diagnostic marker and drug target of the invention is the ATGL Lipase, which can be inhibited by e.g. siRNAs and compounds with any of the following structures (I).Type: ApplicationFiled: March 31, 2010Publication date: September 13, 2012Inventors: Robert Zimmerman, Rudolf Zechner, Günther Haemmerle, Gerald Höfler, Suman Das, Achim Lass
-
Publication number: 20120225417Abstract: The invention concerns methods and kits for evaluating the semen quality. The invention also concerns compounds and compositions for preserving a sperm sample, especially during cryopreservation. The invention is based on a correlation between sperm phosphodiesterase (PDE) activity and sperm fertility and on the use of selective phosphodiesterase inhibitors, more particularly PDE10 inhibitors.Type: ApplicationFiled: February 3, 2012Publication date: September 6, 2012Applicants: I'Alliance Boviteq Inc., Université LavalInventors: François Richard, Christine Guillemette, Juan Pablo Aragon, Audrey Hébert, Pierre Leclerc, Patrick Blondin
-
Publication number: 20120227120Abstract: Provided are hydrolases, including lipases, saturases, palmitases and/or stearatases, and polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. Further provided are polypeptides, e.g., enzymes, having a hydrolase activity, e.g., lipases, saturases, palmitases and/or stearatases and methods for preparing low saturate or low trans fat oils, such as low saturate or low trans fat animal or vegetable oils, e.g., soy or canola oils.Type: ApplicationFiled: May 14, 2012Publication date: September 6, 2012Applicant: DSM IP ASSETS B.V.Inventors: Tim HITCHMAN, Christopher L. G. DAYTON, Katie A. KLINE, Jonathan LYON, Mark A. WALL, Nelson R. BARTON
-
Publication number: 20120219979Abstract: Provided herein are methods for assessing the risk a test subject with heart failure has of experiencing a major adverse cardiac event, requiring revascularization, requiring a heart transplant, requiring unscheduled hospitalization for heart failure, progression of heart failure status, or any combination thereof. Also provided herein are methods for assessing the risk a test subject has of developing heart failure. The present methods comprise determining the levels of paraoxonase 1 activity in the serum, non-chelated plasma, or both in the test subject and comparing the level of PON1 activity in the test subject's sample with a control or baseline value based on levels of PON1 activity in serum, non-chelated plasma, or both samples from a population of control subjects. Also provided herein are kits useful in assessing such risks.Type: ApplicationFiled: August 19, 2010Publication date: August 30, 2012Applicant: The Cleveland Clinic FoundationInventor: Stanley L. Hazen
-
Publication number: 20120214860Abstract: The present invention relates to a method of regulating the expression level of survival of motor neuron 1 (SMN1) comprising administering to a subject in need thereof a therapeutically effective amount of ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) regulator and a pharmaceutically acceptable carrier. The present invention also relates to a method of detecting enzyme activity of ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) in human fibroblasts comprising detecting protein expression level of survival of motor neuron 1 (SMN1).Type: ApplicationFiled: February 23, 2011Publication date: August 23, 2012Applicant: KAOHSIUNG MEDICAL UNIVERSISTYInventors: Yuh-Jyh Jong, Shih-Hsien Hsu, Jan-Gowth Chang
-
Publication number: 20120214154Abstract: The disclosed technology relates to a genetically engineered biological indicator, comprising: at least one test organism and at least one reporter gene suitable for producing an indicator enzyme, the reporter gene being taken up by the test organism; and at least one repressor gene that inhibits expression of the reporter gene until the reporter gene is exposed to at least one inducer. A process and an apparatus for using the biological indicator are disclosed.Type: ApplicationFiled: May 2, 2012Publication date: August 23, 2012Applicant: AMERICAN STERILIZER COMPANYInventors: Phillip P. Franciskovich, William A. Yirava, Tricia A. Cregger
-
Patent number: 8247190Abstract: This invention relates to altered forms of members of the RNase A superfamily. An RNase A can be modified to be cytotoxic by altering its amino acid sequence so that it is not bound easily by the ribonuclease inhibitor while still retaining catalytic properties. While earlier work had identified some modifications to RNase A that would result in cytotoxicity, the use of the FADE algorithm for molecular interaction analysis has led to several other locations that were candidates for modification. Some of those modifications did result in RNase A variants with increase cytotoxicity.Type: GrantFiled: July 11, 2011Date of Patent: August 21, 2012Assignee: Wisconsin Alumni Research FoundationInventors: Ronald T. Raines, Julie C. Mitchell, Thomas J. Rutkoski
-
Publication number: 20120208221Abstract: This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the lysosomal sulfatase enzyme.Type: ApplicationFiled: February 10, 2012Publication date: August 16, 2012Applicant: BIOMARIN PHARMACEUTICAL INC.Inventors: Michel C. Vellard, Vish Koppaka, Melita Dvorak-Ewell, Erno Pungor, Charles Hague
-
Publication number: 20120210467Abstract: In alternative embodiments, the invention provides phosphatidylinositol-specific phospholipase C (PI-PLC) enzymes, nucleic acids encoding them, antibodies that bind specifically to them, and methods for making and using them. Industrial methods and products comprising use of these phospholipases are also provided. In certain embodiments, provided herein are methods for hydration of non hydratable phospholipids (NHPs) within a lipid matrix. The methods enable migration of NHPs to an oil-water interface thereby allowing the NHPs to be reacted and/or removed from the lipids. In certain embodiments, provided is a method for removing NHPs, hydratable phospholipids, and lecithins from vegetable oils to produce a degummed oil or fat product that can be used for food production and/or non-food applications. In certain embodiments, provided herein are methods for hydration of NHPs followed by enzymatic treatment and removal of various phospholipids and lecithins.Type: ApplicationFiled: October 8, 2010Publication date: August 16, 2012Applicant: DSM IP ASSETS B.V.Inventors: Nelson R. Barton, Tim S. Hitchman, Jonathan D. Lyon, Eileen O'Donaghue, Mark A. Wall
-
Publication number: 20120190013Abstract: The present invention provides novel methods for determining the presence or amount of a hydrolytic enzyme in a sample, based on novel substrates for the enzymes, and also provides compositions and methods that provide highly sensitive assay methods for such hydrolytic enzymes.Type: ApplicationFiled: January 17, 2012Publication date: July 26, 2012Inventors: Chong-Sheng Yuan, Xiaoru Chen
-
Publication number: 20120190054Abstract: Enzymes and/or polypeptides and/or mixtures of interest are evaluated during hydrolysis of cellulosic material by the use of indicator constituents such as fluorescent agents, resulting in efficient high-throughput analysis of enzymes and/or polypeptides. A high-throughput assay for the analysis of inter alia, pretreated corn stover (PCS) hydrolysis is also disclosed.Type: ApplicationFiled: July 13, 2010Publication date: July 26, 2012Applicant: NOVOZYMES A/SInventors: Marco Malten, Keith McFarland
-
Publication number: 20120178117Abstract: A method of lipid assay characterized by assaying the lipids contained in a blood component in the presence of an organic silicon compound. The method can cause specific conditions for direct methods while satisfying requirements such as no influence on precision of assay, no burden on assay apparatus, and easy availability.Type: ApplicationFiled: August 4, 2011Publication date: July 12, 2012Applicant: DAIICHI PURE CHEMICALS CO., LTD.Inventors: Mitsuaki YAMAMOTO, Shoko Yamamoto, Mitsuhiro Nakamura, Kazunori Saito
-
Patent number: 8216799Abstract: It is an object of the present invention to provide a dry analytical element for pancreatic lipase analysis having high selectivity with respect to pancreatic lipase, whose multianalyte correlation has been improved. The present invention provides a dry analytical element for measurement of pancreatic lipase contained in a body fluid, which comprises at least one development layer and/or reagent layer containing diglyceride or triglyceride of long-chain alkyl fatty acid having 12 to 22 carbon atoms, monoglyceride lipase, and a glycerine measurement reagent, wherein the development layer and/or the reagent layer comprise two or more types of anionic surfactants and at least one type of the anionic surfactant is alkylarylsulfonate.Type: GrantFiled: June 11, 2008Date of Patent: July 10, 2012Assignee: Fujifilm CorporationInventors: Shigeki Kageyama, Hideaki Tanaka
-
Publication number: 20120171190Abstract: Methods for diagnosing chronic diarrhea and other gastrointestinal conditions. In the methods, a sample of gastrointestinal secretions is obtained from a control group; or a group who has been diagnosed with either healthy gastrointestinal tracts or with a gastrointestinal condition, like chronic diarrhea. The control group samples are analyzed in any suitable manner to determine the levels of gastrointestinal secretions, including one or more autophagy-related proteins, cytokeratins, digestive enzymes, or other proteins. The results of the sample analysis are used to create a database containing profiles of normal and abnormal gastrointestinal secretions. As the database is created and specific secretion level abnormalities are identified, patients may be diagnosed with these abnormalities and be treated by adjusting the levels of specific secretions.Type: ApplicationFiled: March 7, 2012Publication date: July 5, 2012Inventor: Thomas M. Donndelinger
-
Publication number: 20120171709Abstract: The present invention relates to the field of microbiological testing of food. It relates to a method for identifying bacteria of the Bacillus cereus group, comprising the steps consisting in: bringing a sample that may contain bacteria of the Bacillus cereus group, a reaction medium comprising at least one fluorescent phosphatidylcholine phospholipase C substrate and an inhibitor of Gram-negative bacteria into contact, in a container; incubating all of the above together; identifying the bacteria of the Bacillus cereus group by detecting the PC-PLC substrate hydrolysis reaction, in which the pH of the reaction medium and the time necessary for detecting the PC-PLC substrate hydrolysis reaction carried out are adapted in such a way that said hydrolysis reaction by the bacteria of the Bacillus cereus group is detected before the hydrolysis of the PC-PLC substrate by the Gram-positive bacteria other than those belonging to the Bacillus cereus group, and potentially present in the sample, is detectable.Type: ApplicationFiled: September 16, 2010Publication date: July 5, 2012Applicant: bioMerieux, SAInventors: Marie Cellier, John Mills, David Mosticone, Sylvain Orenga, Antoine Vimont
-
Publication number: 20120165387Abstract: The invention provides an improved design for the construction of extensible nucleic acid-based, ligand-controlled regulatory systems, and the nucleic acid regulatory systems resulting therefrom. The invention contemplates improving the design of the switches (ligand-controlled regulatory systems) through the design of an information transmission domain (ITD). The improved ITD eliminates free-floating ends of the switching and the competing strands, and localizes competitive hybridization events to a contiguous strand of competing and switching strands in a strand-displacement mechanism-based switch, thereby improving the kinetics of strand-displacement. The improved regulatory systems have many uses in various biological systems, including gene expression control or ligand-concentration sensing.Type: ApplicationFiled: August 14, 2008Publication date: June 28, 2012Inventors: Christina D. Smolke, Maung Nyan Win, Chase Beisel
-
Publication number: 20120164671Abstract: Systems and methods are provided for monitoring a immunosuppressant drug level and renal function, hepatic function, or a combination thereof in a patient, comprising obtaining a small volume blood sample from the patient; determining the level of at least one immunosuppressant drug in the small volume blood sample and determining the level of a second immunosuppressant drug or analyzing the renal function, the hepatic function, or a combination thereof in the patient. In some embodiments, the immunosuppressant drug levels are determined using a liquid chromatography tandem mass spectrometry (LC-MS/MS) procedure. Also provided are kits for use in any of the systems and methods described herein.Type: ApplicationFiled: February 29, 2012Publication date: June 28, 2012Inventor: Pleasant Fite Hooper
-
Publication number: 20120165404Abstract: Methods of treating a subject having a condition characterized by at least one of neurodegeneration and neuroinflammation are provided. Methods of reducing astrogliosis in a subject having a condition characterized by increased astrogliosis are also provided. Methods of providing neuroprotection to a subject in need thereof are also provided.Type: ApplicationFiled: April 29, 2010Publication date: June 28, 2012Applicant: Biogen Idec MA Inc.Inventor: Matvey Lukashev
-
Publication number: 20120149046Abstract: This invention relates to bioluminescent methods for detecting specific target bacteria, such as E. coli, coliforms, Enterococcus spp, Listeria spp and S. aureus in samples. The sample to be tested is incubated in a non-selective growth medium for up to 8 hours to produce a sample culture and which is then mixed with detection reagents. The detection reagents include a lysis reagent which disrupts bacterial cells in the sample, a pro-luciferin molecule which is specifically converted into luciferin by said target bacteria; and luminescence reagents which produce a luminescent signal in the presence of luciferin. The mixture of sample culture and detection reagents is then incubated and the luminescent signal from the reaction mixture measured.Type: ApplicationFiled: August 20, 2010Publication date: June 14, 2012Inventors: James Paul Meighan, Frederic Nason
-
Patent number: 8198038Abstract: The present invention relates to a plasma biomarker for diagnosing hepatocellular carcinoma (HCC), in particular to the discovery of a protein in plasma using 2-D fluorescence differential gel electrophoresis (2-D DIGE), immunoprecipitation and Nano-liquid chromatography mass spectrometry (Nano-LC-MS/MS) system that was unknown on the basis of conventional techniques. By demonstrating the presence of liver carboxylesterase 1 (hCE1) in human plasma and confirming that its secretion level is higher in patients with HCC than in healthy volunteers, this invention may be used as a screening method to diagnose HCC at an early stage.Type: GrantFiled: October 1, 2008Date of Patent: June 12, 2012Assignee: Industry-Academic Cooperation Foundation, Yonsei UniversityInventors: Young-Ki Paik, Keun Na
-
Publication number: 20120142038Abstract: Methods of assaying enzyme-mediated oxidative demethylation are provided according to embodiments of the present invention which includes combining, under reaction conditions, an oxidative demethylation enzyme, a substrate for the oxidative demethylation enzyme and a formaldehyde detection reagent. Detection of fluorescence is indicative of formaldehyde generated by oxidative demethylation of the substrate by the enzyme, the fluorescence resulting from reaction of formaldehyde and the formaldehyde detection reagent.Type: ApplicationFiled: February 14, 2012Publication date: June 7, 2012Inventors: Russell Hart, Barbara Scheuer, Raymond Trievel
-
Publication number: 20120141630Abstract: Lipolytic enzymes which improve the properties of dough or baked products generally have a high activity towards lipids which are capable of forming a hexagonal phase, and a screening method was developed on this basis. The improved properties may include a larger loaf volume, an improved shape factor, an improved crumb structure, reduced dough stickiness, improved dough stability and/or improved tolerance towards extended proofing. The advantageous lipid-degrading enzymes have higher activity towards MGDG and/or unsaturated phosphatidyl ethanolamines (APE, PE) than towards DGDG, PC, PS, PI, PG, saturated phosphatidyl ethanolamines, ALPE and/or triglicerides.Type: ApplicationFiled: February 6, 2007Publication date: June 7, 2012Applicant: NOVOZYMES A/SInventors: Christel Thea Jorgensen, Luise Erlandsen, Lone Dybdal Nilsson, Kim Borch, Jesper Vind
-
Publication number: 20120135441Abstract: Preparation and isolation of amino vinyl cyclopropane carboxylic acid derivatives and salts thereof, methods of resolving enantiomers, and methods of identifying compositions and/or enzymes that are capable of resolving racemic or partially enantiomerically enriched mixtures.Type: ApplicationFiled: January 2, 2012Publication date: May 31, 2012Applicants: DR. REDDY'S LABORATORIES, INC., DR. REDDY'S LABORATORIES LTD.Inventors: Ian N. Taylor, Michael C. Lloyd, Adrian Heseltine
-
Publication number: 20120135438Abstract: The invention concerns a medium for detecting, identifying and differentiating a microorganism strain in a liquid medium by contacting said liquid sample with a combination of chromogens substrates of enzymes expressed or not by the strain to be detected, the final coloration of the mixture being detectable in the wavelengths of the visible light.Type: ApplicationFiled: February 1, 2012Publication date: May 31, 2012Inventor: Alain Rambach
-
Patent number: 8187832Abstract: A method of detecting an amount of a cholinesterase inhibitor in a sample comprising steps of: (a) contacting the sample with an agent capable of recovering the cholinesterase inhibitor from the sample so that the cholinesterase inhibitor is recovered, wherein the agent comprises a reactivity towards phosphyl moieties; (b) isolating the recovered cholinesterase inhibitor from the sample; (c) contacting the isolated cholinesterase inhibitor from step (b) with a test cholinesterase wherein the cholinesterase activity of the test cholinesterase before step (a) is known; and (d) measuring the cholinesterase activity to determine the amount of cholinesterase inhibitor in the sample based on the inhibition of the test cholinesterase activity from the known activity of the test cholinesterase before step (a).Type: GrantFiled: November 26, 2007Date of Patent: May 29, 2012Assignee: DSO National LaboratoriesInventors: Weng Keong Loke, Yong Teng Tan, Josefina Seow
-
Publication number: 20120129788Abstract: The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for malignant, hormone-sensitive prostate cancer, wherein the expression of the marker is increased when comparing the expression in malignant, hormone-sensitive prostate cancer tissue, to the expression in normal tissue or benign prostate tumor tissue, and the use of PDE4D7 as a diagnostic marker for malignant, hormone-sensitive prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating malignant, hormone-sensitive prostate cancer, a corresponding detection method, a method allowing to discriminate between a benign and malignant hormone-sensitive prostate cancer and a method of data acquisition, as well as corresponding immunoassays. The present invention also relates to a method of identifying an individual for eligibility for malignant, hormone-sensitive prostate cancer as well as an immunoassay for stratifying an individual with such prostate cancer.Type: ApplicationFiled: May 11, 2010Publication date: May 24, 2012Applicants: THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW, KONINKLIJKE PHILIPS ELECTRONICS N.V.Inventors: Ralf Hoffmann, Miles Douglas Houglas, David James Peter Henderson
-
Patent number: 8178311Abstract: The present invention is intended to provide a method for simultaneously measuring cholesterol in low density lipoprotein and total cholesterol as test components in blood. Specifically, a method is used for simultaneously measuring cholesterol in low density lipoprotein and total cholesterol in a biological sample, whereby cholesterol in low density lipoprotein and total cholesterol in a biological sample are quantified with a single measurement.Type: GrantFiled: February 9, 2009Date of Patent: May 15, 2012Assignee: Denka Seiken Co., Ltd.Inventor: Hiroshi Matsui
-
Publication number: 20120108493Abstract: The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting.Type: ApplicationFiled: December 18, 2009Publication date: May 3, 2012Inventors: Denis Bouvier, Thibaut Crepin, Rob Rulgrok, Alexander Dias, Stephen Cusack
-
Patent number: 8168406Abstract: The present invention provides a method for producing a dry analytical element for measurement of pancreatic lipase contained in a body fluid which contains triglyceride of long chain alkyl fatty acid having 12 to 22 carbon atoms, monoglyceride lipase, and a glycerine measurement reagent, and comprises a water-impermeable support and at least one spreading or reagent layer, said method comprising the step of coating an emulsion/dispersion solution of triglyceride with an average particle size of 1 ?m or less.Type: GrantFiled: March 24, 2009Date of Patent: May 1, 2012Assignee: Fujifilm CorporationInventors: Jun Arakawa, Nobuhito Masuda, Kentaro Nakamura, Shigeki Kageyama